TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study

TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study

Caiyun Lu,1,* Renming Liu,2,* Yanyang Zhang,1,* Junyang Luo,1 Cheng Luo,3 Zaibo Jiang,1 Mingsheng Huang,1 Chunhui Qiu,4 Junwei Chen1 1Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, People’s Re...

Full description

Saved in:
Bibliographic Details
Main Authors: Lu C, Liu R, Zhang Y, Luo J, Luo C, Jiang Z, Huang M, Qiu C, Chen J
Format: Article
Language:English
Published: Dove Medical Press 2025-07-01
Series:Journal of Hepatocellular Carcinoma
Subjects:
hepatocellular carcinoma
conversion therapy
transarterial chemoembolization
Lenvatinib
programmed death-1 inhibitor
Online Access:https://www.dovepress.com/tace-combined-with-lenvatinib-pd-1-versus-tace-monotherapy-as-conversi-peer-reviewed-fulltext-article-JHC
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/tace-combined-with-lenvatinib-pd-1-versus-tace-monotherapy-as-conversi-peer-reviewed-fulltext-article-JHC

Similar Items